ZNF143 Antibody

What is ZNF143 and why is it important in research?

ZNF143 is a 626 amino acid protein characterized by seven C2H2-type zinc fingers that function as a transcriptional activator. It is predominantly localized in the nucleus and demonstrates ubiquitous expression, with highest levels observed in ovarian tissue . ZNF143 has significant research importance due to its role in binding to the SPH motif in promoters of small nuclear RNAs (snRNAs), indicating a crucial function in regulating genes involved in RNA processing and transcriptional control . Additionally, ZNF143 regulates genes vital for maintaining genomic stability by ensuring accurate DNA replication and repair . Recent research has revealed that ZNF143 specifically activates nuclear-encoded mitochondrial genes, making it an essential regulator of mitochondrial function, cell proliferation, and differentiation .

What types of ZNF143 antibodies are currently available for research?

Several types of ZNF143 antibodies are available for research applications, including:

• Rabbit polyclonal antibodies: These recognize recombinant fragment proteins within human ZNF143, specifically from amino acid 450 to the C-terminus. They are suitable for immunohistochemistry on paraffin-embedded tissues (IHC-P) and have been validated for human samples .

• Mouse monoclonal antibodies: The L-26 clone is an IgG1 kappa light chain antibody that detects ZNF143 protein across multiple species including mouse, rat, and human. This antibody has been validated for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA) .

Researchers should note that antibody selection should align with their experimental needs, target species, and planned application.

How can I verify the specificity of a ZNF143 antibody?

Verifying antibody specificity is crucial for obtaining reliable results. For ZNF143 antibodies, consider these methodological approaches:

• Western blot analysis: Confirm the antibody detects a band of approximately 72 kDa (the predicted molecular weight of ZNF143).

• ChIP-seq validation: Compare binding patterns with known ZNF143 binding sites. De novo motif analysis of ChIP-seq peaks should reveal canonical ZNF143 sequence motifs. As demonstrated in recent research, 95% of authentic ZNF143 binding peaks contain variants of the ZNF143 motif, with the core sequence TGGGA recognized by zinc fingers 5 and 6 .

• Antibody validation using tagged proteins: Compare results from antibodies against endogenous ZNF143 with those against tagged versions (e.g., HA-tagged or FLAG-tagged ZNF143) as control experiments. Studies have shown that ChIP-seq data from HA-tagged ZNF143 had a high degree (86%) of overlap with previously published ZNF143 ChIP-seq data .

• Knockout/knockdown controls: Include ZNF143 knockout or knockdown samples to verify signal loss when the protein is depleted. Recent studies using the dTAG degradation system demonstrated complete protein degradation within 30 minutes of treatment, providing an excellent negative control .

What are the optimal conditions for using ZNF143 antibodies in ChIP experiments?

For optimal ChIP experiments using ZNF143 antibodies, consider the following methodological approaches:

• Antibody selection: Recent research has identified potential cross-reactivity issues with some ZNF143 antibodies. Specifically, the polyclonal anti-ZNF143 Proteintech 16618-1-AP antibody shows significant overlap (>40%) with CTCF peaks, suggesting cross-reactivity . For more specific results, consider using antibodies against tagged versions of ZNF143 (FLAG-tagged or HA-tagged) or validate your antibody thoroughly against known controls.

• ChIP protocol optimization:

  • Crosslinking: Standard 1% formaldehyde for 10 minutes at room temperature

  • Sonication: Adjust to generate fragments of 200-500 bp

  • Antibody amount: 2-5 μg per ChIP reaction

  • Washing conditions: Use stringent washing buffers to reduce background

• Controls: Include IgG controls and, ideally, a ZNF143 knockout/knockdown sample to confirm specificity.

• Analysis parameters: When analyzing ZNF143 binding sites, look for its characteristic 29-base wide recognition sequence. Recent research has shown that ZNF143 binds a sequence-degenerate motif with the core sequence TGGGA .

How can I use ZNF143 antibodies to study its role in transcriptional regulation?

ZNF143 functions as both an activator and repressor of transcription, making it an interesting subject for transcriptional regulation studies. Consider these methodological approaches:

• Combined ChIP-seq and transcriptome analysis:

  • Perform ChIP-seq to identify ZNF143 binding sites

  • Conduct RNA-seq or PRO-seq (nascent RNA profiling) after ZNF143 depletion

  • Integrate these datasets to identify direct ZNF143 target genes

• Rapid protein degradation systems: Utilize systems like dTAG for rapid ZNF143 depletion to distinguish direct from indirect effects. Recent research demonstrated that less than 10% of ZNF143 remains after 15 minutes of dTAG V-1 treatment .

• Reporter assays: Use luciferase reporter constructs containing ZNF143 binding sites to investigate its activator/repressor functions in different contexts.

• Context-specific analysis: Distinguish between ZNF143-activated and ZNF143-repressed genes by examining:

  • DNA binding context (location relative to transcription start sites)

  • Competition with other transcription factors

  • Occlusion of transcription initiation sites

  • Potential roadblock to RNA Polymerase during early elongation

What techniques are most effective for detecting ZNF143 in different sample types?

The effectiveness of detection techniques varies by sample type:

For all techniques, include appropriate controls and validate the antibody using multiple methods before proceeding with experiments.

How do I investigate the dual activator/repressor functions of ZNF143?

ZNF143 has been shown to function as both an activator and a repressor of transcription in a context-specific manner. To investigate this duality:

• Integrated genomic approach:

  • Perform ChIP-seq to map ZNF143 binding sites

  • Conduct PRO-seq after rapid ZNF143 depletion to identify direct transcriptional changes

  • Classify genes as ZNF143-activated (decreased expression upon depletion) or ZNF143-repressed (increased expression upon depletion)

• Analyze binding site context:

  • For repressed genes: Examine if ZNF143 binding occludes transcription initiation sites or promoter-proximal elements

  • For activated genes: Analyze co-occurrence with other transcription factors and cofactors

• Mechanistic validation experiments:

  • Mutagenesis of ZNF143 binding sites in reporter constructs

  • Protein-protein interaction studies to identify different cofactor complexes that mediate activation versus repression

  • CRISPR-based manipulation of binding sites in their native context

Recent research has revealed that ZNF143 can paradoxically retain its activator function while directly repressing target genes in cis. When bound near transcription initiation sites, ZNF143 can compete with more efficient activators, physically occlude transcription initiation sites, or act as a roadblock to RNA Polymerase during early elongation .

How can I resolve contradictory results regarding ZNF143 binding and function?

Contradictory results are common in ZNF143 research due to:

• Antibody cross-reactivity issues:

  • Recent studies have shown that a commonly used ZNF143 antibody (Proteintech 16618-1-AP) cross-reacts with CTCF, leading to incorrect associations with chromatin loops

  • Solution: Use antibodies against tagged ZNF143 versions for validation or carefully validated antibodies against endogenous protein

• Context-dependent function:

  • ZNF143 can both activate and repress genes depending on the binding context

  • Solution: Perform fine-mapping of binding relative to transcription start sites and analyze co-occurring factors

• Direct versus indirect effects:

  • Chronic depletion studies may capture indirect effects

  • Solution: Use rapid protein degradation systems (e.g., dTAG) to identify immediate transcriptional changes within 30 minutes of ZNF143 depletion

• Cell type-specific effects:

  • ZNF143 function may vary across cell types

  • Solution: Compare results across multiple cell lines and primary cells

When encountering contradictory results, carefully document the experimental conditions, cell types, antibodies used, and depletion methods to identify potential sources of variability.

What are the key considerations when studying ZNF143's role in DNA repair and genomic stability?

ZNF143 plays important roles in DNA repair and genomic stability. Key methodological considerations include:

• DNA damage induction protocols:

  • Use different DNA-damaging agents (UV, ionizing radiation, chemical agents) to understand pathway-specific involvement

  • Include time-course experiments to capture early versus late responses

• Protein recruitment studies:

  • ChIP-seq before and after DNA damage to track ZNF143 redistribution

  • Co-immunoprecipitation to identify DNA repair factors that interact with ZNF143

• Functional readouts:

  • Comet assay to measure DNA break repair efficiency

  • γ-H2AX foci resolution as a marker of DNA damage repair

  • Cell survival assays following DNA damage in ZNF143-depleted versus control cells

• Target gene analysis:

  • Identify DNA repair genes regulated by ZNF143

  • Rescue experiments to determine which target genes mediate ZNF143's effect on genome stability

Research has shown that ZNF143 expression is upregulated in response to DNA damage, highlighting its essential function in DNA repair mechanisms critical for maintaining genomic stability and cellular integrity .

What are common issues with ZNF143 antibodies and how can they be resolved?

Common issues with ZNF143 antibodies include:

• Cross-reactivity with CTCF:

  • Issue: Some ZNF143 antibodies, particularly the Proteintech 16618-1-AP, show significant overlap with CTCF binding sites

  • Resolution: Compare results with tagged versions of ZNF143 (HA-tag or FLAG-tag) or use well-validated antibodies. One study found a 10-fold difference in the number of peaks detected by the Proteintech antibody compared to anti-FLAG-ZNF143 antibody in K562 cells

• Batch-to-batch variability:

  • Issue: Polyclonal antibodies may show variability between batches

  • Resolution: Validate each new lot against known controls and consider using monoclonal antibodies for more consistent results

• Non-specific binding:

  • Issue: Background signals that obscure specific ZNF143 detection

  • Resolution: Optimize blocking conditions, increase washing stringency, and validate with ZNF143 knockout/knockdown controls

• Limited cross-species reactivity:

  • Issue: Some antibodies may work in limited species

  • Resolution: Carefully check validation data for your species of interest. For example, the mouse monoclonal L-26 antibody has been validated for mouse, rat, and human samples

How should I interpret ChIP-seq data for ZNF143 binding sites?

Proper interpretation of ZNF143 ChIP-seq data requires:

• Motif analysis:

  • Authentic ZNF143 binding sites should contain variants of the ZNF143 motif

  • The core sequence TGGGA is recognized by zinc fingers 5 and 6

  • Recent research identified a 29-base binding motif, similar to the biochemically determined 27-mer core motif

  • Approximately 95% of genuine peaks contain recognizable ZNF143 motif variants

• Peak classification:

  • Consider the genomic context of binding (promoters, enhancers, gene bodies)

  • Analyze distance to transcription start sites (TSS)

  • Examine co-occupancy with other transcription factors

• Functional correlation:

  • Integrate with transcriptome data after ZNF143 depletion

  • Classify peaks associated with activated versus repressed genes

• Quality control:

  • Assess biological replicates for reproducibility

  • Verify peak enrichment compared to input controls

  • Check for potential artifacts from cross-reactivity with other proteins

A recent study found that while most peaks (95%) contained recognizable ZNF143 motifs, 5% of binding sites did not have identifiable motifs yet remained sensitive to ZNF143 depletion, suggesting functional low-affinity binding sites .

How can I differentiate between direct and indirect effects of ZNF143 on gene expression?

Differentiating between direct and indirect effects requires careful experimental design:

• Rapid protein depletion systems:

  • Use systems like dTAG for fast ZNF143 degradation (>90% within 15 minutes)

  • Perform nascent RNA profiling (PRO-seq) at early time points (30 minutes) to capture primary transcriptional responses before secondary effects occur

• Binding site correlation:

  • Direct targets should show ZNF143 binding near their regulatory regions

  • Integrate ChIP-seq with transcriptome data to identify genes with both binding and expression changes

• Binding site manipulation:

  • Use CRISPR-Cas9 to mutate specific ZNF143 binding sites

  • Direct targets should show similar expression changes as seen with ZNF143 depletion

• Context analysis for repressed genes:

  • Examine if ZNF143 binding occludes other activator binding sites

  • Check if ZNF143 binds near transcription initiation sites where it can physically block RNA Polymerase

  • Consider competition mechanisms where ZNF143 competes with more efficient activators

Recent research revealed that while ZNF143 can directly repress gene expression, this repression mechanism (termed "cis repression") may only account for up to 30% of direct ZNF143-repressed targets. Alternative mechanisms like relieving competition for cofactors may explain why additional genes are repressed indirectly .

What are emerging areas of ZNF143 research that may require specialized antibody applications?

Several emerging research areas for ZNF143 present new opportunities for antibody applications:

• ZNF143's role in mitochondrial function:

  • Recent research established ZNF143 as a conserved transcriptional regulator of nuclear-encoded mitochondrial genes

  • Future applications: Chromatin immunoprecipitation followed by mass spectrometry (ChIP-MS) to identify mitochondria-specific cofactors interacting with ZNF143

• Context-specific transcriptional regulation:

  • ZNF143 functions as both an activator and repressor depending on genomic context

  • Future applications: Proximity labeling techniques (BioID, APEX) combined with ZNF143 antibodies to identify context-specific protein interactions

• ZNF143 in development and differentiation:

  • ZNF143 has been identified as an essential regulator of organismal development

  • Future applications: Antibodies optimized for tissue sections and developmental time courses

• ZNF143 in disease contexts:

  • Aberrant ZNF143 function may contribute to various pathologies

  • Future applications: Phospho-specific antibodies to detect post-translational modifications of ZNF143 in disease states

These emerging areas will benefit from continued refinement of antibody specificity and the development of modification-specific antibodies to capture the functional dynamics of ZNF143 in various contexts.

What methodological advances are needed to better understand ZNF143 function?

Advancing our understanding of ZNF143 function will require:

• Enhanced spatiotemporal resolution:

  • Development of antibodies compatible with live-cell imaging

  • Optimization for super-resolution microscopy techniques

  • Single-cell approaches to detect cell-to-cell variability in ZNF143 binding and function

• Refinement of rapid protein modulation systems:

  • Further development of systems like dTAG for studying immediate effects of ZNF143 loss

  • Optogenetic or chemical biology approaches to modulate ZNF143 activity rather than abundance

• Domain-specific functional analysis:

  • Generation of domain-specific antibodies to study different functional modules of ZNF143

  • Development of conformation-specific antibodies to detect active versus inactive states

• Integration with emerging technologies:

  • Optimization for CUT&Tag or CUT&RUN methods for improved chromatin profiling

  • Compatibility with spatial transcriptomics approaches to understand tissue-specific functions